Full Press Release Details
Nevro Reports First Quarter 2015 Financial Results
Menlo Park, Calif., May 11, 2015 - Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based
neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.
Accomplishments & Highlights:
I am pleased that adoption of HF10 therapy has continued at a strong pace in the first quarter in European Union and Australian markets, said
Michael DeMane, Chairman and CEO of Nevro. As a result, more patients in need are afforded the benefits of Nevro s best-in-class spinal cord stimulation technology. Now, with PMA approval and the first FDA SCS superiority label, these
meaningful patient benefits will for the first time be made available to U.S. chronic pain patients.
First Quarter Financial Results
Revenue for the three months ended March 31, 2015 was $9.7 million versus $6.7 million during the same period of the prior year, representing 45% growth
as reported, or 70% growth on a constant currency basis. The net revenue increase was primarily attributable to continued adoption of the Senza system.
Gross profit for the three months ended March 31, 2015 was $5.8 million, representing a 60% gross margin, up from $3.7 million, representing a 55% gross
margin, in the same period of the prior year. Product costs as a percent of revenue decreased as average cost per unit benefited from economies of scale with higher unit volumes compared to the same period last year. While revenues were negatively
impacted by the appreciation of the U.S. dollar, costs were primarily incurred in U.S. dollars, which negatively impacted the overall gross margin for the period.
Operating expenses for the three months ended March 31, 2015 were $18.1 million, an increase of 66%
compared to $10.9 million in the same period of the prior year. The increase in operating expenses was driven primarily by increased headcount and related personnel costs for the sales and marketing organization in preparation for the U.S.
commercial launch as well as an increase in general and administrative costs associated with being a public company.
Loss from operations for the first
quarter of 2015 was $12.3 million, compared to $7.2 million for the same period of the prior year.
Guidance for Full Year 2015
The company is reiterating its previously issued guidance, estimating international revenue for the full year 2015 to be in the range of $36 to $38
million, which represents an increase from 2014 in the range of 10.5% to 16.7% on a reported basis, and the range of 25.8% to 32.8% using foreign exchange rates from the first quarter of 2015.
Webcast and Conference Call Information
host a conference call today beginning at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may dial (877) 201-0168 for domestic callers, or (647) 788-4901 for international callers (Conference ID:
41475428), or access the webcast on the Investors section of the Company s web site at: www.nevro.com. The webcast will be available on the Company s web site for two weeks following the completion of the call.
Headquartered in Menlo Park, California,
Nevro is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro s
proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements with respect to our business, capital resources, strategic
initiatives and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including regarding our beliefs about making Senza available in
the United States; continuing adoption of Senza in international markets; and our expectations for international revenue for the full year 2015. These forward-looking statements are based upon information that is currently available to us or our
current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; the timing of our U.S. commercial launch of Senza; our ability to
manufacture our products to meet demand;
the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights
and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability
to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on March 18, 2015 and our Quarterly Report on Form 10-Q
that we expect to file on May 11, 2015, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our
forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the quarter ended March 31, 2015 are not necessarily indicative
of our operating results for any future periods.
Investor Relations Contact:
Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||||||||
| 2015 | 2014 | |||||||
| (unaudited) | ||||||||
| Revenue | $ | 9,662 | $ | 6,664 | ||||
| Cost of revenue | 3,873 | 2,999 | ||||||
| Gross profit | 5,789 | 3,665 | ||||||
| Operating expenses: | ||||||||
| Research and development | 4,998 | 4,696 | ||||||
| Sales, general and administrative | 13,130 | 6,210 | ||||||
| Total operating expenses | 18,128 | 10,906 | ||||||
| Loss from operations | (12,339 | ) | (7,241 | ) | ||||
| Other income (expense): | ||||||||
| Interest income (expense), net | (569 | ) | 40 | |||||
| Other income (expense), net | (1,010 | ) | 238 | |||||
| Loss before income taxes | (13,918 | ) | (6,963 | ) | ||||
| Provision for income taxes | 142 | 93 | ||||||
| Net loss | (14,060 | ) | (7,056 | ) | ||||
| Accretion of convertible preferred stock to redemption value | (43 | ) | ||||||
| Net loss attributable to common stockholders | (14,060 | ) | (7,099 | ) | ||||
| Changes in foreign currency translation adjustment | (123 | ) | ||||||
| Changes in gains (losses) on short-term investments | (79 | ) | (13 | ) | ||||
| Net change in other comprehensive loss | (202 | ) | (13 | ) | ||||
| Comprehensive loss | $ | (14,262 | ) | $ | (7,112 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.57 | ) | $ | (6.60 | ) | ||
| Weighted average shares used to compute net loss per share, basic and diluted | 24,849,229 | 1,075,932 |
Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31, 2015 | December 31, 2014 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 21,984 | $ | 25,287 | ||||
| Short-term investments | 137,232 | 151,521 | ||||||
| Accounts receivable, net | 7,314 | 6,610 | ||||||
| Inventories, net | 18,236 | 14,856 | ||||||
| Prepaid expenses and other current assets | 3,026 | 2,851 | ||||||
| Total current assets | 187,792 | 201,125 | ||||||
| Property and equipment, net | 1,189 | 647 | ||||||
| Other assets | 2,333 | 424 | ||||||
| Restricted cash | 906 | 300 | ||||||
| Total assets | $ | 192,220 | $ | 202,496 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 8,151 | $ | 4,460 | ||||
| Accrued liabilities and other | 5,278 | 6,338 | ||||||
| Total current liabilities | 13,429 | 10,798 | ||||||
| Notes payable | 19,569 | 19,511 | ||||||
| Other long-term liabilities | 104 | 117 | ||||||
| Total liabilities | 33,102 | 30,426 | ||||||
| Stockholders equity | ||||||||
| Common stock, $0.001 par value 290,000,000 shares authorized, 24,896,511 and 24,865,491 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively | 25 | 25 | ||||||
| Additional paid-in capital | 295,255 | 293,945 | ||||||
| Accumulated other comprehensive income (loss) | (125 | ) | 77 | |||||
| Accumulated deficit | (136,037 | ) | (121,977 | ) | ||||
| Total stockholders equity | 159,118 | 172,070 | ||||||
| Total liabilities and stockholders equity | $ | 192,220 | $ | 202,496 |